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Abstract
Background: Mammalian target of rapamycin complex 1 (mTORC1) is a protein kinase that relays nutrient availability signals
to control numerous cellular functions including autophagy, a process of cellular self-eating activated by nutrient depletion.
Addressing the therapeutic potential of modulating mTORC1 signaling and autophagy in human disease requires active
chemicals with pharmacologically desirable properties.
Methodology/Principal Findings: Using an automated cell-based assay, we screened a collection of .3,500 chemicals and
identified three approved drugs (perhexiline, niclosamide, amiodarone) and one pharmacological reagent (rottlerin) capable
of rapidly increasing autophagosome content. Biochemical assays showed that the four compounds stimulate autophagy
and inhibit mTORC1 signaling in cells maintained in nutrient-rich conditions. The compounds did not inhibit mTORC2,
which also contains mTOR as a catalytic subunit, suggesting that they do not inhibit mTOR catalytic activity but rather
inhibit signaling to mTORC1. mTORC1 inhibition and autophagosome accumulation induced by perhexiline, niclosamide or
rottlerin were rapidly reversed upon drug withdrawal whereas amiodarone inhibited mTORC1 essentially irreversibly. TSC2,
a negative regulator of mTORC1, was required for inhibition of mTORC1 signaling by rottlerin but not for mTORC1 inhibition
by perhexiline, niclosamide and amiodarone. Transient exposure of immortalized mouse embryo fibroblasts to these drugs
was not toxic in nutrient-rich conditions but led to rapid cell death by apoptosis in starvation conditions, by a mechanism
determined in large part by the tuberous sclerosis complex protein TSC2, an upstream regulator of mTORC1. By contrast,
transient exposure to the mTORC1 inhibitor rapamycin caused essentially irreversible mTORC1 inhibition, sustained
inhibition of cell growth and no selective cell killing in starvation.
Conclusion/Significance: The observation that drugs already approved for human use can reversibly inhibit mTORC1 and
stimulate autophagy should greatly facilitate the preclinical and clinical testing of mTORC1 inhibition for indications such as
tuberous sclerosis, diabetes, cardiovascular disease and cancer.
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Introduction
The cellular processes linked to growth are tightly modulated by
nutrient levels. Anabolic functions such as ribosome biogenesis and
protein synthesis are inhibited under conditions of nutrient
limitation, while catabolic pathways such as autophagy are
activated. Autophagy, a process of cellular self-eating, can
temporarily compensate for lack of extracellular nutrients by
engulfing cytoplasmic components within double-membraned
autophagosomes, degrading them by fusion with lysosomes and
releasing building blocks for macromolecular synthesis [1,2].
Mammalian target of rapamycin complex 1 (mTORC1) plays a
critical role in coupling nutrient sensing to these anabolic and
catabolic processes [3]. When nutrients are available, mTORC1 is
switched on and negatively regulates autophagy while positively
regulating ribosome biogenesis and protein synthesis [4,5].
Conversely, nutrient limitation turns off mTORC1 signaling,
leading to inhibition of cell growth and stimulation of autophagy.
mTORC1 is a protein complex composed of the serine/
threoninekinasemTOR,thescaffolding proteinraptor andmLST8
[3]. mTORC1 controls the initiation step of protein synthesis
through the phosphorylation of eukaryotic initiation factor 4E-
binding proteins (4E-BPs) [6,7] and of ribosomal S6 kinases (S6Ks)
[8]. 4E-BPs are a family of small proteins that associate with eIF4E,
an mRNA cap-binding protein. eIF4E, together with eIF4G and
eIF4A form the eIF4F complex that recruits the small (40S)
ribosomal subunit to the 59-end of mRNA. 4E-BPs and eIF4G bind
to overlapping regions in eIF4E such that binding of 4E-BPs to
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7124eIF4E precludes the binding of eIF4G and blocks recruitment of
the ribosome to the message [3]. The binding of 4E-BP1 to eIF4E is
blocked through mTORC1-dependent phosphorylation of multiple
residues on 4E-BP1. mTORC1 also phosphorylates the S6Ks that
in turn phosphorylate multiple translation components including
eIF4B and ribosomal protein S6. However, the role of phosphor-
ylation of these proteins in stimulating protein synthesis remains to
be elucidated [9].
Studies in metazoans and lower eukaryotes indicate that
TORC1 plays an important role in the control of autophagy.
Deletion in Drosophila of TOR or Rheb, an activator of TORC1,
enhances autophagy even under the nutrient-rich conditions in
which autophagy is typically downregulated [10]. Conversely,
deletion of Drosophila TSC2, an inhibitor of Rheb/TORC1
signaling, blocks autophagy induced by nutrient withdrawal [10].
In budding yeast, TOR has been proposed to inhibit autophagy
through phosphorylation of the Atg1/Atg13 complex [11], which
regulates the recruitment of proteins to, and development of,
nascent autophagosomes [12]. Phosphorylation of Atg13 by TOR
precludes the binding of Atg13 to Atg1, resulting in a marked
decrease in the kinase activity of Atg1 [11]. A putative human
homologue of Atg13 has been identified [13] that forms a complex
with ULK1 and FIP200 that may be directly regulated by
mTORC1 [14]. In keeping with genetic data, rapamycin, a
specific inhibitor of mTORC1, induces autophagy in mammalian
cells as well as in S. cerevisiae and D. melanogaster [11,15–17].
In addition to promoting cell survival in starvation conditions,
autophagyplaysakeyroleincellularhomeostasisbydegrading long-
lived proteins, damaged organelles and abnormal protein aggregates
whose accumulation can lead to cell death, muscular- and neuro-
degenerative diseases and cancer [5,18]. Defects in autophagy may
contribute to tumorigenesis, by allowing the accumulation of
damaged mitochondria, which can lead to genetic instability [5].
Autophagy is also frequently observed in dying cells, prompting the
suggestion that it can constitute a death mechanism [18]. Therefore,
defects in autophagy could also contribute to cancer cell survival [5].
Addressing the therapeutic potential of modulating mTORC1
signaling and autophagy in human disease requires active
chemicals with pharmacologically desirable properties [2,19,20].
We have developed an assay to detect chemicals that cause a rapid
increase in cellular autophagosome content. A screen of .3,500
approved and off-patent medications, as well as compounds with
known pharmacological activity led to the identification of three
drugs approved for use in humans (amiodarone, niclosamide and
perhexiline) and the pharmacological agent rottlerin. Consistent
with their ability to modulate autophagy, we show that these
chemicals also control mTORC1 signaling. Rottlerin inhibits
mTORC1 signaling via TSC2 while the other drugs inhibit
mTORC1 signaling in a TSC2-independent manner. Transient
exposure to niclosamide, perhexiline or rottlerin causes reversible
inhibition of mTORC1 signaling and is not toxic to cells in
conditions of nutrient and growth factor sufficiency. However,
these drugs selectively kill cells in starvation conditions. Drugs
already approved for human use that can reversibly inhibit
mTORC1 signaling and stimulate autophagy are valuable
pharmacological tools to evaluate the therapeutic potential of
manipulating mTORC1 and autophagy in disease.
Results
Development of an automated microscopy screen for
chemical modulators of autophagy
Upon autophagyinduction, thecytosolicAtg8 protein,also called
LC3, is recruited to the membrane of nascent autophagosomes and
controls autophagosome expansion [21]. LC3 is synthesised as a
precursor protein whose C-terminus is cleaved by a cysteine
protease to expose a glycine residue that is subsequently conjugated
tophosphatidylethanolaminebya ubiquitin-likesystem[22–24].To
develop a screening assay for chemical modulators of autophagy,
human breast cancer MCF-7 cells were stably transfected with a
plasmid for expression of LC3 linked at its N-terminus to EGFP
(Fig. 1a). In complete cell culture medium containing glucose,
amino acids and serum, EGFP-LC3 fluorescence was largely diffuse
throughout the cytoplasm with few dots denoting basal autophago-
some formation (Fig. 1b). The number of EGFP-LC3 dots rapidly
increased within 4 h exposure to the mTORC1 inhibitor
rapamycin, or to amino acid- and serum-free medium (Fig. 1b;
Supplementary Figure S1), conditions that are known to stimulate
autophagy [25]. We wished to identify chemicals that, like
rapamycin and starvation, also rapidly increase EGFP-LC3
punctate staining in cells maintained in nutrient-rich conditions,
where autophagy is normally downregulated. The microscopy assay
was automated using a high-content screening instrument pro-
grammed to detect and quantitate punctate EGFP-LC3 fluores-
cence. The Z-factor [26] for the assay was 0.55, appropriate for use
in screening (Fig. S2). As demonstrated by the automated assay,
withdrawal of amino acids and serum for 4 h caused a 3-fold
increase in punctate EGFP-LC3 fluorescence intensity (Fig. S1b).
A collection of 3,584 drugs and pharmacologically active
chemicals was tested at a concentration of ,15 mM for 4 h in
complete cell culture medium. Chemicals causing a $80%
reduction in cell number were considered overtly toxic and were
disregarded. Compounds that induced a $3-fold increase in
punctate EGFP-LC3 intensity were designated as active (Fig. S2b).
Four active chemicals, perhexiline, niclosamide, amiodarone and
rottlerin (Fig. 1c), showed concentration-dependent activity
ranging from 7- to 15-fold increased punctate EGFP-LC3
fluorescence intensity at their optimal concentration (Fig. 1d).
Amiodarone has previously been found to reduce the accumu-
lation of expanded polyglutamine aggregates [27] and to enhance
the clearance of mutant huntingtin and A53T a-synuclein in
human cells [28], likely through the stimulation of autophagy.
Rottlerin has recently been reported to induce autophagy in a
PKCh-independent manner in fibrosarcoma cells [29]. To our
knowledge, neither niclosamide nor perhexiline have been
previously reported to modulate autophagy.
Characterization of amiodarone, rottlerin, niclosamide
and perhexiline as stimulators of autophagy
To verify that the punctate EGFP-LC3 fluorescence induced by
the four chemicals represented autophagosome formation rather
than, for instance, fluorescent drug precipitates, EGFP-LC3
fluorescence was examined at higher resolution by laser confocal
microscopy. As expected, non-treated cells showed diffuse EGFP-
LC3 fluorescence with few punctate structures (Fig. 2). Incubation
with perhexiline, niclosamide, amiodarone or rottlerin for 4 h
induced the appearance of a large number of EGFP-LC3-labeled
cytoplasmicvesiclesconsistentwithautophagosomeformation(Fig.2).
To ensure that punctate fluorescence detected in drug-treated
cells was due to modulation of autophagy, we next monitored
EGFP-LC3 processing and degradation. Recruitment of LC3 to
nascent autophagosomes involves its proteolytic cleavage and
lipidation [30]. This processing step, which also occurs with
EGFP-LC3, yields a polypeptide (EGFP-LC3II) with increased
electrophoretic mobility. When autophagosomes fuse with lyso-
somes, EGFP-LC3II is degraded by lysosomal hydrolases and the
labile LC3II moiety is degraded faster than the more stable EGFP
moiety, leading to transient accumulation of EGFP, which is also
mTORC1 Signaling Inhibitors
PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e7124Figure 1. Cell-based assay for the identification of chemical modulators of autophagy and identification of amiodarone, niclosamide,
perhexiline and rottlerin as modulators of autophagy. (a) Schematic representation of the EGFP-LC3 puncta formation assay used to screen for
chemical modulators of autophagy. (b) Punctate EGFP-LC3 accumulation upon treatment with rapamycin or nutrient deprivation. MCF-7 cells stably
expressing EGFP-LC3 were incubated without or with 20 nM rapamycin in complete cell culture medium or in medium lacking serum and amino acids
for 4 h. EGFP-LC3 punctate staining was visualised by automated microscopy as described in Materials and Methods. (c) Chemical structures of
perhexiline, niclosamide, amiodarone and rottlerin. (d) Quantitation of punctate EGFP-LC3 accumulation upon incubation with the active chemicals.
MCF-7 cells stably expressing EGFP-LC3 were incubated for 4 h with different concentrations of the chemicals and EGFP-LC3 puntacte staining was
quantitated using the automated microscopy assay.
doi:10.1371/journal.pone.0007124.g001
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therefore be considered as characteristic proteolytic intermediates
in autophagy. A time-dependent accumulation of free EGFP was
readily observed upon incubation of MCF-7 cells stably expressing
EGFP-LC3 with rapamycin (Fig. S1b), consistent with the ob-
served time-dependent increase in punctate EGFP-LC3 (Fig. S1a).
Similarly, serum deprivation caused an accumulation of free
EGFP within 1 h (Fig. S3a). To verify that the four active
chemicals indeed modulated autophagy, we examined the
appearance of these bands following incubation with a range of
concentrations of the chemicals and for different times.
Incubation with perhexiline at varying concentrations (3 to
10 mM) for 4 h caused a concentration-dependent accumulation of
free EGFP (Fig. 3, top panel) as well as a small but appreciable
increase in EGFP-LC3 lipidation. Niclosamide led to the accumu-
lation of EGFP-LC3II at concentrations as low as 1 mM (Fig. 3, top
panel). Free EGFP did not accumulate, but faster migrating bands
correspondingtoEGFP proteolysis products were readilydetectable
(Fig. 3). Lipidated EGFP-LC3 (EGFP-LC3II) was detected within
15 min and it continued to accumulate over time (Fig. 4b).
Amiodarone also led to the accumulation of EGFP-LC3II (Fig. 4c,
5a) and a substantial increase in free EGFP at 10 mM or higher
concentrations (Fig. 3, 5a) within 2 to 4 h (Fig. 4c). Like niclosamide
and amiodarone, rottlerin caused the accumulation of EGFP-LC3II
and free EGFP, as well as proteolytic fragments of EGFP at 0.3 mM
and higher concentrations (Fig. 3).Lipidated EGFP-LC3 was visible
within 30 min incubation while free EGFP could be detected
between 2 and 4 h (Fig. 4d).
Bafilomycin A1 is an inhibitor of the vacuolar-type H
+-ATPase
that prevents lysosomal acidification, leading to inhibition of
lysosomal hydrolases and fusion of autophagosomes with lysosomes
[32]. Cells were next incubated with perhexiline, niclosamide,
amiodarone, rottlerin or rapamycin in the absence or presence of
bafilomycin A1 and EGFP-LC3 processing and degradation was
monitored by western blotting. Bafilomycin A1 clearly blocked the
accumulation of free EGFP by the four active chemicals and by
rapamycin (Fig. 5), indicating that EGFP-LC3 proteolysis required
autophagosome-lysosome fusion and lysosomal hydrolase activity.
The observation that all four chemicals stimulated the processing
and degradation of EGFP-LC3 in a bafilomycin A1-dependent
manner is strong evidence that the chemicals increase autophagic
flux and therefore stimulate autophagy.
Perhexiline, niclosamide, amiodarone and rottlerin inhibit
mTORC1 signaling
Autophagyisregulated throughbothmTORC1-dependent and-
independent mechanisms [33]. Since perhexiline, niclosamide,
amiodarone and rottlerin stimulate autophagy, we next asked
whether any of these chemicals inhibited mTORC1 signaling.
mTORC1 phosphorylates S6Ks at Thr
389 [8]. S6K phosphoryla-
tion was completely inhibited by rapamycin, as shown by a
disappearance of the phospho-Thr
389 signal and increased
electrophoretic mobility of S6Ks (Fig. S1c). Samples of MCF-7
cells treated with the four chemicals at different concentrations or
for different times were analyzed for mTORC1 activation. MCF-7
cells showed robust mTORC1 activation in complete medium
containingserum and nutrients(Fig. 3–5).Perhexiline caused strong
inhibition of the phosphorylation of p70
S6K and p85
S6K at 10 mM
(Fig. 3) within 30 min and was maximal at 4 h (Fig. 4). Niclosamide
caused a strong reduction of S6K phosphorylation at 1 mMa n d
complete inhibition at 3 and 10 mM (Fig. 3). Partial inhibition was
detectable as early as 5 min after treatment and was essentially
complete after 2 h (Fig. 4). Amiodarone was the least potent of the
compounds, with partial inhibition of S6K phosphorylation at
30 mM and complete inhibition at 50 mM (Fig. 3) and this effect was
only readily detectable after 2 h (Fig. 4). Rottlerin caused partial
inhibition of S6K phosphorylation at 1 mM and complete inhibition
at 3 mM (Fig. 3). Inhibition was detectable within 2–4 h (Fig. 4).
mTORC1 signaling also mediates the phosphorylation of
multiple residues on 4E-BP1, including Thr
37/46 and Ser
65.
Figure 2. Visualization of punctate EGFP-LC3 in cells treated with autophagy-modulating compounds. MCF-7 cells stably expressing
EGFP-LC3 were treated for 4 h with DMSO (control), 10 mM perhexiline, 10 mM niclosamide, 50 mM amiodarone or 3 mM rottlerin. Photographs show
stacks of confocal sections spanning the entire cell thickness.
doi:10.1371/journal.pone.0007124.g002
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DMSO, strongly inhibited phosphorylation at Ser
65 at 1 h and
completely abolished it at 4 h as judged by the decreased binding
of phospho-specific antibody and increased electrophoretic
mobility of 4E-BP1 (Fig. 6a). These chemicals also decreased the
phosphorylation of Thr
37/46 in 4E-BP1 and 4E-BP2 (Fig. 6a). The
phosphorylation of Ser
65 requires both amino acids and growth
factors, whereas phosphorylation of Thr
37/46 is strongly stimulated
by amino acids alone [34]. To examine whether perhexiline,
niclosamide, amiodarone and rottlerin inhibited the amino acid-
dependent phosphorylation of Thr
37/46, MCF-7 cells were
exposed to perhexiline, rottlerin, amiodarone or niclosamide in
medium lacking serum for 1 h or 4 h. All four chemicals reduced
the amino acid-mediated phosphorylation of Thr
37/46 in 4E-BP1
and 4E-BP2, although not completely (Fig. S3b).
Hypophosphorylated 4E-BPs bind to eIF4E thereby precluding
the association of eIF4E with eIF4G and the assembly of the eIF4F
complex. Phosphorylation of Ser
65 has been suggested to be
particularly important in preventing the re-association of 4E-BP1
with eIF4E [35]. Since the four active chemicals completely block
phosphorylation of Ser
65 in 4E-BP1, we next analyzed their effect
on the binding of 4E-BPs to eIF4E by affinity chromatography.
MCF-7 cells were propagated in complete medium to near-
confluence and then incubated with perhexiline, niclosamide,
amiodarone, rottlerin or DMSO (vehicle) for 4 h. Cellular extracts
were incubated with 7-methylguanosine-59-triphosphate beads
and the pull-down material probed with antisera against eIF4E,
eIF4G and 4E-BP1 in a western blot. In nutrient-rich conditions,
where mTORC1 signaling is switched on and 4E-BP1 is
hyperphosphorylated, eIF4E associates tightly with eIF4G but
not 4E-BP1 (Fig. 6b, lane 6). Inhibition of mTORC1 by
rapamycin increases the binding of 4E-BPs to eIF4E with the
concomitant release of eIF4G [4]. Similarly, each of the four
chemicals increased the binding of 4E-BP1 to eIF4E and partially
decreased the association of eIF4G with eIF4E (Fig. 6b).
The four active chemicals and rapamycin also inhibited
mTORC1 signaling equally strongly in the absence or in the
presence of bafilomycin A1, even though the latter inhibited
EGFP-LC3 processing and degradation (Fig. 5). Moreover,
bafilomycin A1 did not inhibit mTORC1 signaling (Fig. 5).
Therefore, the four active chemicals inhibit mTORC1 signaling
at concentrations that closely parallel those at which they stimulate
autophagosome formation as well as EGFP-LC3 processing and
degradation. To our knowledge, perhexiline, niclosamide and
amiodarone have not previously been shown to inhibit mTORC1
signaling. Rottlerin was previously found to inhibit S6K
phosphorylation in rat and cat cardiomyocytes [36,37]. Perhex-
iline, amiodarone and rottlerin inhibited mTORC1 signaling
much more slowly than rapamycin, which caused complete
inhibition within 5 min (not shown), suggesting that they do not
inhibit mTORC1 directly. The onset of mTORC1 signaling
inhibition by niclosamide was rapid (5 min) but complete
inhibition required a longer incubation. The observation that
bafilomycin A1 inhibits EGFP-LC3 processing and degradation
but that it does not affect the inhibition of mTORC1 signaling by
the four active chemicals shows that mTORC1 signaling
inhibition is not a consequence of stimulation of autophagy and
is consistent with stimulation of autophagy lying downstream of
mTORC1 inhibition.
Perhexiline, niclosamide, amiodarone and rottlerin do
not inhibit mTORC2 signaling
mTOR is present in two distinct complexes: mTOR complex 1
(mTORC1) which phosphorylates S6Ks, 4E-BPs and PRAS40
[8,38–40] and mTORC2 which catalyzes the phosphorylation of
PKB/Akt and SGK1 [41–43]. Insulin receptor substrate-1 (IRS-1),
and to a lesser extent IRS-2, protein levels are regulated by S6K1.
Hyperactivation of S6K1 signaling leads to transcriptional inhibi-
tionofthe IRS-1gene anddegradation ofIRS-1andIRS-2proteins
[44]. This is evident in both TSC1 and TSC2 null mouse embryo
fibroblasts (MEFs) which exhibit reduced insulin receptor/PI3K
signaling and PKB/Akt phosphorylation at Ser
473 as a result of
mTORC1/S6K1 signaling hyperactivation [45]. Prolonged treat-
ment (24 h) of cells that display elevated mTORC1/S6K signaling
with rapamycin restores PI3K signaling and PKB/Akt phosphor-
ylation on Ser
473 [44,45]. We reasoned that other inhibitors of
mTORC1/S6K signaling, such as those identified in this screen,
might also increase PKB/Akt phosphorylation. As predicted, MCF-
7 cells, which exhibit elevated mTORC1 signaling like TSC1 or
TSC2 null MEFs [46,47], showed increased phosphorylation of
Ser
473 in PKB/Akt when treated with niclosamide, perhexiline,
amiodarone or rottlerin (Fig. 3, 6). The increase in PKB/Akt Ser
473
phosphorylation closely paralleled the decrease in mTORC1
activity as a function of concentration for the four chemicals
(Fig. 3). The observation that the four chemicals increased PKB/
Akt phosphorylation at Ser
473 instead of decreasing it shows that
they inhibited mTORC1 but not mTORC2 signaling.
Reversibility of mTORC1 signaling inhibition and
autophagosome accumulation
MCF-7 cells expressing EGFP-LC3 were incubated with
perhexiline, niclosamide, rottlerin, or amiodarone for 4 h in
Figure 3. Concentration-dependent stimulation of EGFP-LC3
processing and inhibition of mTORC1 signaling by perhexiline,
niclosamide, amiodarone and rottlerin. MCF-7 cells stably
expressing EGFP-LC3 were treated for 4 h with chemicals at the
indicated concentrations or with 20 nM rapamycin. EGFP-LC3 process-
ing was monitored by probing lysates with anti-GFP antibody, mTORC1
activity by probing lysates with antisera against phosphorylated (Thr
389)
S6K and total S6K, and mTORC2 activity with antisera against
phosphorylated (Ser
473) PKB/Akt and total PKB/Akt. b-tubulin immuno-
staining was used as a protein loading control.
doi:10.1371/journal.pone.0007124.g003
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phosphorylation was measured immediately after washing (t=0)
and at 2 h, 4 h and 20 h after. Cells were similarly treated with
rapamycin for comparison. All five chemicals inhibited the
phosphorylation of p70
S6K and p85
S6K at Thr
389 (Fig. 7a), as
demonstrated above. Within 2 h following removal of perhexiline
or niclosamide, mTORC1 signaling increased substantially and
was fully restored by 4 h (Fig. 7a). Inhibition of mTORC1
signaling by rottlerin persisted for 2 h after drug removal but
returned to control levels between 4 h and 20 h. By contrast,
mTORC1 signaling remained completely inhibited 20 h after
removal of amiodarone or rapamycin, indicating that these drugs
act essentially irreversibly. Similarly, punctate EGFP-LC3 staining
disappeared rapidly upon withdrawal of perhexiline, niclosamide
Figure 4. Time-dependent stimulation of EGFP-LC3 processing and inhibition of mTORC1 signaling by perhexiline, niclosamide,
amiodarone and rottlerin. MCF-7 cells stably expressing EGFP-LC3 were treated for the indicated times with 10 mM perhexiline, 10 mM
niclosamide, 50 mM amiodarone or 3 mM rottlerin. Immunoblotting was carried out using the antisera indicated.
doi:10.1371/journal.pone.0007124.g004
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tion of autophagy for the former three compounds (Fig. 7b).
TSC2 is essential only for rottlerin-mediated inhibition of
mTORC1 signaling
TSC1/TSC2 plays an important role in the control of
mTORC1 signaling. Insulin and growth factors have been
proposed to turn on mTORC1 signaling through inactivation of
TSC2 [48,49], which functions as a GTPase-activating protein for
the small G-protein Rheb [50–53].
Having established that perhexiline, niclosamide, amiodarone
and rottlerin inhibit mTORC1 signaling, we sought to determine
whether these drugs acted upstream of TSC2. To address this
question we made use of TSC2
2/2 and TSC2
+/+ mouse embryo
fibroblasts also lacking both p53 alleles (hereafter referred to as
TSC2
2/2 and TSC2
+/+ MEFs) [54]. Near-confluent MEFs were
incubated with each of the four chemicals or rapamycin in
complete medium for 4 h and lysates were analysed for mTORC1
signaling. As originally reported by Zhang et al. [54], TSC2
2/2
MEFs exhibited elevated mTORC1 signaling relative to TSC2
+/+
cells and in both cases rapamycin completely abolished mTORC1
signaling, in accordance with the fact that it inhibits mTORC1
signaling downstream of TSC1/TSC2 (Fig. 8a). Niclosamide,
amiodarone and perhexiline inhibited mTORC1 signaling in
TSC2
+/+ as well as in TSC2
2/2 MEFs (Fig. 8a), indicating that
TSC2 is not required for these drugs to inhibit mTORC1
signaling. These results imply that niclosamide, perhexiline and
amiodarone inhibit mTORC1 signaling downstream of the
tuberous sclerosis complex or through a different signaling
cascade.
Figure 5. Effect of bafilomycin A1 on EGFP-LC3 processing and
inhibition of mTORC1 signaling by perhexiline, niclosamide,
amiodarone and rottlerin. MCF-7 cells stably expressing EGFP-LC3
were treated for 4 h with 10 mM perhexiline, 10 mM niclosamide, 50 mM
amiodarone or 3 mM rottlerin without or with 100 nM bafilomycin A1.
doi:10.1371/journal.pone.0007124.g005
Figure 6. Inhibition of 4E-BP phosphorylation and function by
perhexiline, niclosamide, amiodarone and rottlerin. MCF-7 cells
stably expressing EGFP-LC3 were incubated with 10 mM perhexiline,
10 mM niclosamide, 50 mM amiodarone, 3 mM rottlerin or DMSO for 1 h
or 4 h in complete medium. (a) EGFP-LC3 processing and mTORC1 and
mTORC2 activation were monitored by immunoblotting as described in
the legend to Fig. 3. Lysates were also probed with antisera to
phosphorylated (Thr
37/46 or Ser
65) 4E-BPs and total 4E-BP1. (b) eIF4E
was purified from cell extracts by m
7GTP affinity chromatography as
described in Materials and Methods and the purified material was
probed with antisera against eIF4E, eIF4G and 4E-BP1.
doi:10.1371/journal.pone.0007124.g006
mTORC1 Signaling Inhibitors
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+/+ MEFs,
as judged by the decreased phosphorylation of S6K at Thr
389 and
4E-BP1 at Ser
64 (Fig. 8a, b). However, unlike the other drugs,
rottlerin failed to inhibit mTORC1 signaling in TSC2
2/2 cells
(Fig. 8a, b), suggesting that it inhibits mTORC1 signaling by
activating TSC2. The observation that rottlerin failed to inhibit
mTORC1 signaling in TSC2
2/2 cells provided an opportunity to
test whether it induces autophagy through inhibition of mTORC1
signaling. Rottlerin caused LC3II accumulation in both TSC2
+/+
and TSC2
2/2 cells, indicating that inhibition of mTORC1 is not
required for rottlerin-mediated LC3 processing (Fig. 8a, b).
Niclosamide, rottlerin and perhexiline selectively kill
MEFs in starvation conditions
Having identified chemicals that stimulate autophagy and
inhibit mTORC1 signaling, we next investigated their effect on
cell survival and proliferation. TSC2
+/+ and TSC2
2/2 MEFs
were exposed to varying concentrations of the chemicals in
complete medium. After 4 h, the chemicals were removed and the
ability of the cells to recover and proliferate was monitored 48 h
later. Incubation with niclosamide or rottlerin had no effect on
viability or proliferation of MEFs, while perhexiline caused a small
reduction in total cell number (Fig. 9). These results indicate that
transient inhibition of mTORC1 signaling and stimulation of
autophagy in complete medium had no adverse effect on
subsequent cell survival or proliferation. Amiodarone was
moderately toxic towards MEFs, with an IC50 of about 20 mM
(Fig. 9), presumably resulting from acting on other cellular targets.
Rapamycin decreased the proliferation of TSC2
+/+ and TSC2
2/2
cells but did not induce cell death (Fig. 9), consistent with its
known cytostatic activity and with its apparently irreversible
mTORC1 inhibition [55].
This experiment was repeated using different starvation
conditions (Fig. 9). Incubation of MEFs with DPBS (medium
lacking glucose, amino acids and serum) for 4 h resulted in a small
reduction in cell number at 48 h. Strikingly, addition of
Figure 7. Reversibility of mTORC1 inhibition and EGFP-LC3 punctate fluorescence accumulation. Cells were incubated for 4 h with
10 mM perhexiline, 10 mM niclosamide, 50 mM amiodarone, 3 mM rottlerin, 20 nM rapamycin or DMSO. Drugs were washed away and cells were
incubated in drug-free medium for the indicated times. (a) mTORC1 activity was measured by western blotting using phospho-specific and total S6K
antibodies. b-tubulin immunostaining was used as a gel loading control. (b) EGFP-LC3 punctate staining was measured using the automated
microscopy assay.
doi:10.1371/journal.pone.0007124.g007
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+/+ cell
death. Perhexiline also caused TSC2
+/+ cell death in DPBS, but
only at high concentrations. Amiodarone showed moderate
toxicity in complete medium but induced extensive cell death in
DPBS. Supplementing DPBS with amino acids did not protect the
cells from drug-induced death whereas supplementing with
glucose increased survival considerably during exposure to
niclosamide, rottlerin or amiodarone, and fully for perhexiline.
Addition of both glucose and serum to DPBS rendered cells
resistant to niclosamide, rottlerin and perhexiline. By contrast,
rapamycin was not any more toxic to cells in DPBS or other
starvation conditions than in complete medium.
The observation that some chemicals that inhibit mTORC1
signaling and stimulate autophagy also selectively killed cells in
starvation conditions was not anticipated given the established role
of autophagy in promoting survival during starvation. Therefore,
we next investigated the death mechanism involved. TSC2
+/+
MEFs were exposed to chemicals for 4 h in complete medium or
in starvation conditions. The drugs were then washed away and
after 24 h, the cells were stained with FITC-Annexin V and
propidium iodide. Annexin V binds to phosphatidylserine on the
outer leaflet of the plasma membrane and labels cells actively
undergoing apoptosis while propidium iodide is excluded by viable
cells with an intact plasma membrane and therefore labels dead
cells. Flow cytometry analysis revealed that in starvation
conditions, the four chemicals caused a considerable increase in
cells labeled with FITC-Annexin and propidium iodide (Fig. 10).
Autophagic cell death is not associated with increased Annexin V
binding [56], indicating that the chemicals trigger apoptotic cell
death in starvation conditions.
TSC2 is an important determinant of cellular sensitivity to
active chemicals in starvation conditions
TSC2
+/+ and TSC2
2/2 MEFs responded similarly to each of
the four chemicals in complete medium but not in starvation
conditions (Fig. 9). TSC2
2/2 cells were generally more resistant
than TSC2
+/+ MEFs to exposure to niclosamide, rottlerin and
perhexiline in the different starvation conditions. For example,
exposure of TSC2
2/2 cells to niclosamide or rottlerin in DPBS
strongly decreased cell survival but addition of glucose was
sufficient to almost completely rescue TSC2
2/2 cell survival,
whereas both glucose and serum were necessary to prevent killing
of TSC2
+/+ by these chemicals (Fig. 9). By contrast, the effect of
rapamycin was similar in TSC2
+/+ and TSC2
2/2 cells under all
conditions, consistent with it acting downstream of TSC1/TSC2.
These results show that the tuberous sclerosis complex plays an
important role in the selective killing of cells by niclosamide,
rottlerin and perhexiline in starvation conditions.
Discussion
This study identifies four chemicals (perhexiline, niclosamide,
amiodarone and rottlerin) that stimulate autophagy and inhibit
mTORC1 signaling within a few hours in conditions of nutrient
and growth factor sufficiency, under which autophagy is normally
downregulated and mTORC1 signaling switched on. Each of the
four chemicals showed interesting similarities to and differences
from the well-characterized mTORC1 inhibitor rapamycin.
Rapamycin inactivates mTORC1 very rapidly, within a few
minutes of cellular exposure. Niclosamide also rapidly inhibits
mTORC1 signaling but this inhibition is initially partial, complete
inhibition being achieved after 1–2 h incubation. The three other
chemicals required 1–2 h incubation to inhibit mTORC1
signaling, strongly implying that they do not inhibit mTORC1
directly, but target upstream mTORC1 control pathways.
Rapamycin is highly potent, complete mTORC1 inhibition being
achieved at low nanomolar concentrations. Niclosamide is also
Figure 8. Rottlerin inhibits mTORC1 signaling in a TSC2-
dependent manner while perhexiline, niclosamide and amio-
darone do not. (a) TSC2
2/2 or TSC2
+/+ MEFs were incubated in
complete medium with 10 mM perhexiline, 10 mM niclosamide, 3 mM
rottlerin, 50 mM amiodarone, DMSO for 4 h or 100 nM rapamycin for
2h . (b) TSC2
2/2 or TSC2
+/+ MEFs were incubated in duplicate in
complete medium with 4 mM rottlerin for 1 h, 100 nM rapamycin or
DMSO for 30 min. Lysates were analysed by western blotting using the
antisera indicated.
doi:10.1371/journal.pone.0007124.g008
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chemicals inhibit mTORC1 at micromolar concentrations.
Rapamycin inhibits mTORC1 independently of TSC1/TSC2,
similar to amiodarone, perhexiline and niclosamide. By contrast,
rottlerin can only inhibit mTORC1 signaling in TSC2
+/+ cells,
implying that it inhibits mTORC1 signaling upstream of TSC2.
All four compounds selectively inhibit mTORC1 but not
mTORC2 signaling, as does rapamycin.
Notably, the chemicals identified in this study differ from
rapamycin with respect to the reversibility of mTORC1 inhibition.
Rapamycin inhibits mTORC1 signaling irreversibly [55]. By
contrast, inhibition of mTORC1 signaling by niclosamide,
perhexiline and rottlerin is reversed upon drug removal, while
amiodarone is only slowly reversible. Pharmacologically, reversible
inhibition is considered a favorable property, especially for drug
targets whose activity is necessary for normal cellular functions,
because prolonged inhibition caused by irreversible inhibitors can
lead to severe side effects [57]. This property should facilitate the
fine-tuning of chemical inhibition of mTORC1 signaling in cells or
animals for studies of mechanism of action or therapeutic potential.
The effects of transient exposure on cell proliferation and
viability between the four compounds and rapamycin also differed
considerably. Transient exposure to nanomolar concentrations of
rapamycin caused long-lasting inhibition of cell proliferation,
consistent with its irreversible mode of mTORC1 inhibition. By
contrast, 4 h incubation with niclosamide, rottlerin and perhex-
iline at concentrations that were sufficient to profoundly inhibit
mTORC1 signaling and stimulate autophagy had little or no effect
on cell viability or proliferation in cell culture medium containing
nutrients and serum. This result is consistent with the reversible
nature of mTORC1 signaling inhibition by these chemicals and
demonstrates that strong but transient inhibition of mTORC1
signaling and stimulation of autophagy are not deleterious to cells.
The observation that amiodarone killed cells while niclosamide,
perhexiline, rottlerin and rapamycin did not suggests that
amiodarone acts on targets other than mTORC1 and autophagy
to induce toxicity.
The effects of short exposure to the four chemicals on cell
survival and proliferation in starvation conditions also differed
from those of rapamycin. Transient exposure to rapamycin did not
kill cells but was cytostatic and affected equally cells in complete
medium and in starvation conditions. By contrast, the four
autophagy-stimulating chemicals all enhanced to varying degrees
cell killing in starvation conditions, with niclosamide and rottlerin
showing the most pronounced effect. Killing was rescued partially
by glucose and totally by further addition of serum, indicating that
an interplay between energy status sensing, growth factor signaling
and drug action is important for cell death. This observation was
Figure 9. Effect of niclosamide, rottlerin, amiodarone and perhexiline on cell survival in different starvation conditions. TSC2
2/2 and
TSC2
+/+ MEFs wereincubatedfor4 h with different concentrations ofthe chemicalsincompletemediumor inthedifferent starvationconditions shown.
Chemicals and media were washed away and the cells were incubated for 40 h in complete medium without chemicals before measuring cell viability.
doi:10.1371/journal.pone.0007124.g009
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response to starvation and we anticipated that stimulators of
autophagy would increase cell survival in starvation conditions.
However, a form of death termed type II or autophagic death has
been attributed to unregulated autophagy [56,58,59]. It can be
suggested that simultaneous exposure to multiple autophagy
stimuli might overactivate autophagy and transform a normally
protective response into a death mechanism. However this does
not appear to be the case because dying cells showed the presence
of phosphatidylserine on the outer leaflet of their plasma
membrane, indicating that death occurred through apoptosis.
The observation that TSC2
2/2 cells are very significantly, but not
completely, protected from death in starvation firmly implicates
the TSC1/TSC2 signaling cascade in the death mechanism. The
interesting observation that rapamycin does not trigger cell death
in starvation but that upstream inhibitors of mTORC1 signaling
do indicates that death does not result from mTORC1 inhibition
per se. Rather, it implies the involvement of a TSC2-dependent
but mTORC1-independent cell survival pathway. Lee et al [60]
showed that loss of TSC2 activates p53 and increases cell death in
response to glucose starvation and that inactivation of mTORC1
by rapamycin protects TSC2 mutant cells from starvation-induced
death. They did not observe this effect in TSC2
2/2 p53
2/2 cells,
which responded similarly to rapamycin treatment and were as
resistant to glucose starvation as TSC2
+/+ p53
2/2 cells. Since
TSC2
2/2 p53
2/2 cells were used in the present study, the death
Figure 10. Effect of active chemicals on membrane integrity and apoptosis. TSC2
+/+ MEFs were incubated for 4 h with DMSO or with 3 mM
niclosamide, 30 mM amiodarone, 3 mM rottlerin or 10 mM perhexiline in the cell culture media indicated. Chemicals and media were washed away and
the cells were incubated for 24 h in complete medium without chemicals. The extent of cell death and apoptosis was determined by measuring
propidium iodide uptake (PI, y axis; relative fluorescence intensity measured in FL2 channel) and FITC Annexin V staining (x axis; relative fluorescence
intensity measured in FL1 channel) by flow cytometry. Live cells (PI- and Annexin V-negative) appear in the lower left part of the scatter plots while
cells that have died of apoptosis (PI- and Annexin V-positive) appear in the upper right hand part. The numbers in each box indicate the percent of
dead or dying (PI- and/or Annexin V-positive) cells.
doi:10.1371/journal.pone.0007124.g010
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by Lee at al. [60].
Perhexiline, niclosamide, amiodarone and rottlerin most likely
inhibit mTORC1 signaling by acting on upstream regulatory
pathways, unlike the recently described inhibitors of mTORC1/2
Torin1 [61] and Ku-0063794 [62] and the dual PI3k/mTOR
inhibitors PI-103 [63] and NVP-BEZ235 [64], which inhibit these
kinases directly.
Rottlerin is a widely used pharmacological agent believed until
recently to inhibit PKCh selectively. However, it has now been
unequivocally shown that rottlerin does not inhibit this kinase.
Rather, it inhibits potently several other kinases and enzymes
including malate dehydrogenase, activates several types of K
+
channels, and uncouples mitochondrial oxidative phosphorylation
[65]. Consistent with its uncoupling activity, rottlerin has been
reported to reduce cellular ATP levels, causing AMPK activation
through a poorly understood signaling mechanism involving the
tumor suppressor LKB1 [66]. AMPK phosphorylates and
activates TSC2 to switch off mTORC1 signaling [67]. It is
tempting to speculate that rottlerin inhibits mTORC1 signaling
through the phosphorylation of Ser 1345 on TSC2 by AMPK.
However, there are currently no antibodies available to study this
phosphorylation on TSC2. Although it is possible that rottlerin
stimulates autophagy via AMPK, TSC2 and mTORC1, this is
unlikely to be the only mechanism because LC3 processing still
occurs in TSC2
2/2 cells in which rottlerin does not inhibit
mTORC1 signaling.
Niclosamide is a salicylanilide antihelmintic drug that was
approved for use in humans nearly 50 years ago [68,69]. It was
developed on the basis of activity in rodent models of parasitic
worm infection rather than inhibition of a precise cellular target
and its mode of action remains unclear. Niclosamide is believed to
owe its antiparasitic effects to protonophoric activity [69], the
ability of some chemicals to embed themselves within membranes
and, via a continuous cycle, carry protons across membranes along
their concentration gradient. Niclosamide and analogues inhibit
glucose uptake by parasites, possibly by lowering the plasma
membrane potential of tegument cells through protonophoric
activity [70,71]. Niclosamide can also uncouple mitochondrial
oxidative phosphorylation in worms [72] but this is not considered
relevant to antihelmintic activity in the anaerobic intestinal
environment [73]. Niclosamide can also uncouple mitochondrial
oxidative phosphorylation in human cells [74,75], raising the
possibility that it inhibits mTORC1 signaling and stimulates
autophagy by lowering ATP levels in the cell. However, this is not
the case because niclosamide treatment did not significantly
decrease cellular ATP concentration (96.660.3% in niclosamide-
treated cells versus 100.063.3% in control cells treated with
DMSO) during 4 h incubation, and mTORC1 inhibition by
niclosamide did not require TSC2.
Amiodarone is an antianginal and antiarrhythmic drug [76]
that exerts many pharmacological activities including blockage of
multiple ion channels [77]. Interestingly, exposure of yeast to
amiodarone in nutrient-rich medium causes a rapid change in
gene expression pattern resembling that elicited by starvation and
by rapamycin, prompting the authors to suggest that amiodarone
interferes with nutrient sensing and regulatory networks by an
uncharacterized mechanism [78]. Amiodarone inhibited
mTORC1 in a TSC2-independent manner and killed cells in
starvation conditions in a manner that was not affected by TSC2,
suggesting that its mechanism of action differs from that of
rottlerin or niclosamide.
Perhexiline is an antianginal drug with multiple pharmacolog-
ical activities [79]. It was originally designated as a calcium
channel blocker but it shows no such activity at therapeutic
concentrations [80,81]. Rather, there is increasing evidence that it
acts by inhibiting carnitine palmitoyltransferase, an enzyme that
permits the entry of fatty acids into mitochondria [80]. This
inhibition shifts myocardial substrate utilization from fatty acids to
lactate and glucose, which increases ATP generation per unit
oxygen consumed and exerts an oxygen sparing effect on the heart
muscle[80,82,83]. No protonophoric, mitochondrial uncoupling,
or protein kinase inhibition activity has been attributed to this
drug. Perhexiline inhibited mTORC1 in a TSC2-independent
manner but its effects in starvation were not as pronounced as
those of rottlerin, niclosamide or amiodarone.
The four chemicals identified in this study should be useful
pharmacological tools to manipulate mTORC1 signaling and
autophagy in cells and in animal models of disease. Perhexiline can
be administered continuously to humans for many years, with
mean plasma concentrations of ,2 mM without any significant
adverse effects [80,84]. Severe side effects do not occur at serum
concentrations below 5 mM [84]. Perhexiline induced autophago-
some accumulation in the 1–3 mM range and strong mTORC1
inhibition was seen at 10 mM during 4 h exposure, close to
therapeutic concentrations. Niclosamide exerts its antiparasitic
activity in the intestinal lumen and was not designed to be
absorbed through the intestine. Nevertheless, it shows 10% oral
bioavailability and micromolar serum concentrations are achieved
after a single oral dose in animals or humans [85,86]. Intravenous
administration of niclosamide to rats gave rise to a peak plasma
concentration of 25 mM [86]. Niclosamide very strongly inhibited
mTORC1 signaling at concentrations as low as 1 mM. Therefore,
therapeutic inhibition of mTORC1 signaling may be achievable
using niclosamide or a derivative. Amiodarone can be adminis-
tered safely for many years with a mean steady state plasma
concentration of 2 mM. Peak plasma concentrations can be as high
as 60 mM [87]. Amiodarone inhibited mTORC1 signaling at
concentrations above 10 mM. Rottlerin is not an approved drug
but it shows a low toxicity profile in rodents [88] and it inhibits
mTORC1 signaling at 1 mM.
The observation that drugs already approved for human use
can reversibly inhibit mTORC1 and stimulate autophagy in vitro at
concentrations that correspond to or are close to those observed in
the circulation during treatment should greatly facilitate the
preclinical and clinical testing of mTORC1 inhibition in
indications such as tuberous sclerosis, diabetes, cardiovascular
disease, protein misfolding diseases and cancer.
Materials and Methods
Chemicals
Cell culture reagents were purchased from Invitrogen, unless
stated otherwise. General laboratory chemicals were purchased
from Sigma-Aldrich, Fisher Scientific and BDH Inc. The 3,584
chemicals used in the screen were composed of chemicals from the
Prestwick, Sigma LOPAC, Microsource Spectrum and Biomol
natural products collections, and provided by the Canadian
Chemical Biology Network (www.ccbn-rcbc.ca). Perhexiline,
amiodarone, niclosamide, rottlerin, chloroquine and bafilomycin
A1 were also purchased from Sigma-Aldrich. Rapamycin was
from Calbiochem, Hoechst 33342 from Invitrogen and parafor-
maldehyde from BDH.
Plasmids and antibodies
The pEGFP-LC3 vector, previously described by Kabeya et al.
[22], was a kind gift of Dr. Tamotsu Yoshimori (Osaka, Japan).
pRK7 FLAG-tagged human TSC2 [48], was a generous gift from
mTORC1 Signaling Inhibitors
PLoS ONE | www.plosone.org 12 September 2009 | Volume 4 | Issue 9 | e7124Dr. Andrew Tee (Cardiff, UK). Anti-4E-BP1 antibody was
prepared by Dr. Josep Parra and is described in Wang et al.
[34]. Anti-phospho Thr
37/46 4E-BP1 (#9459), anti-phospho Thr
70
4E-BP1 (#9455), anti-phospho Thr
389 S6K (#9205), anti-
phospho Ser
473 Akt (#9271), anti-Akt (#9272), anti-eIF4E
(#9742) and anti-eIF4G (#2498) antibodies were bought from
Cell Signaling Technology (Massachusetts, USA). Anti-S6K C-18
(#230), anti-MAP LC3 H-50 (#28266), anti-TSC2 C-20 (#893),
anti-b-tubulin H-235 (#9104) and anti-phospho Ser
65 4E-BP1
(#18091) antibodies were purchased from Santa Cruz Biotech-
nology, Inc. Anti-GFP antibody (#1814460) was from Roche.
Anti-LC3 antibody was from Nanotools (#0260-100/LC3-2G6).
Cell culture, transfection and starvation procedures
TSC2
2/2/p53
2/2 and TSC2
+/+/p53
2/2 MEFs were a gener-
ous gift of Dr. David Kwiatkowski (Massachusetts, USA) and have
been previously described by Zhang et al. [54]. These cells were
maintained in high glucose Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% (v/v) fetal bovine serum,
100 units/ml penicillin/streptomycin and 2 mM L-glutamine
(Sigma-Aldrich). MCF-7 (Michigan Center Foundation line 7) cells
were transfected with pEGFP-LC3 using Effectene transfection
reagent (#301425, Invitrogen) according to the manufacturer’s
specification. Stably-transfected cells were selected for 2 months in
RPMI-1640 medium supplemented with 400 mg/ml G418
(#V7982, Promega), 100 units/ml penicillin/streptomycin, 1 mM
HEPES, 10% (v/v) foetal bovine serum and 2 g/L sodium
bicarbonate. EGFP-LC3 expressing cells were sorted by fluores-
cence-activated cell sorter and pooled. The pooled cells were
thereafter maintained in the RPMI-1640 medium described above
and used for all experiments. For starvation experiments, cells were
rinsed twice in DPBS (#14040, Invitrogen) before incubations in
the different starvation media. Serum starvation was carried out by
incubating cells in their corresponding medium lacking fetal bovine
serum. Glucose starvation was carried out by incubating cells in
Hank’s Balanced Salt Solution(#37150, StemCell Technologies) or
DPBS supplemented with amino acids from a 10x mixture [39] and
10% (v/v) dialysed foetal bovine serum. For amino acid starvation,
cells were incubated for 4 h in either DPBS containing 11 mM
glucose. Starvation of serum, glucose and amino acids was carried
out by incubating cells in DPBS.
Chemical screen for modulators of autophagy
MCF-7 cells stably expressing EGFP-LC3 were seeded in
PerkinElmer View 96-well plates at 20,000 cells per well. Eighteen
hours after seeding, chemicals were added to each well to a final
concentration of ,15 mM using a Biorobotics Biogrid II robot
equipped witha 0.7 mmdiameter 96-pin tool.Plates were incubated
for 4 h at 37uC. The medium was then removed and the cells were
fixed with 3% (v/v) paraformaldehyde containing 500 ng/ml
Hoechst 33342 for 15 min at room temperature. Fixed cells were
washedonce with PBScontaining 1 mMMgCl2 and0.1 mMCaCl2
and then stored in the same medium at 4uC until plates were ready
for analysis. Plates were read in a Cellomics
TMArrayscan V
TI
automated fluorescence imager. Cells were photographed using a
20x objective in the Hoechst and GFP (XF-100 filter) channels. The
compartment analysis algorithm was used to identify the nuclei,
apply a cytoplasmic mask and quantitate GFP spots in the GFP
channel fixed at 250 pixel intensity units. Fluorescence intensity in
the GFP channel was gated at 10 average pixel intensity units inside
the cytoplasmic mask to select against cells expressing very low levels
of EGFP-LC3. The total pixel intensity for punctate EGFP-LC3 was
acquired as ‘circ spot total intensity ch2’. Wells showing 3-fold or
higher increase in punctate EGFP-LC3 staining over control were
re-examined visually to eliminate any false positives resulting from
precipitation of fluorescent compounds. Compounds inducing a
3-fold or higher increase in punctate EGFP-LC3 staining were
considered ‘hits’. Compounds causing a decrease in cell number to
fewer than 4,000/well were disregarded as toxic chemicals. The
Z-factor of the assay [26] was determined from punctate EGFP-LC3
measured in cells treated with DMSO (negative control) or
chloroquine (positive control).
Cell lysis and protein quantitation
Cells were harvested in the following extraction buffer: 20 mM
Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1% (v/v) Triton X100, 2.5 mM sodium pyrophosphate, 1 mM
b-glycerophosphate supplemented with fresh 1 mM Na3VO4,
1 mM dithiothreitol and 1x complete protease inhibitor cocktail
(#11697498001, Roche Molecular Biochemicals). Lysates were
pre-cleared by centrifugation at 18,000 g for 15 min at 4uC.
Supernatant was collected and protein quantitated using the BCA
protein assay kit (#23227, Pierce).
Viability/proliferation assay
Cells were seeded in 96-well plates at 8000 cells per well and
grown for 18 h. Cells were then treated with chemicals in different
starvation media for 4 h as described above. The drugs and media
were then removed and cells were incubated in complete medium
without drugs. Cell viability/proliferation was measured 48 h later
using the (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium
bromide (MTT) assay (M2128, Sigma) as described [89].
Flow cytometry
After drug treatment, the cell culture medium was collected to
retain floating cells and attached cells were dislodged using EDTA.
Floating and attached cells were combined and harvested by
centrifugation. The cell pellets were suspended in 100 ml binding
buffer (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2)
and incubated with 5 ml FITC Annexin V (BD Biosciences) and
10 ml of a propidium iodide solution (50 mg/ml; Sigma) for 15 min
in the cold. Staining for Annexin V and propidium iodide was
assessed by flow cytometry on a FACSCalibur instrument (BD
Biosciences) followed by data analysis using FlowJo software (Tree
Star Inc).
SDS-PAGE and western blot
EGFP-LC3 processing was assayed by western blot as described
[90]. TSC2 protein levels and S6K phosphorylation were analyzed
by separating protein samples on a 10% acrylamide gel containing
0.1% methylene bisacrylamide. Endogenous LC3 lipidation and
4E-BP1 phosphorylation were assessed by resolving protein
samples on a 13.5% acrylamide gel with 0.36% methylene
bisacrylamide. Resolved protein was subjected to electroblotting
onto polyvinylidene fluoride membrane, blocked with 5% (w/v)
fat-free milk and incubated with antisera as indicated. Endogenous
LC3 and 4E-BP1 proteins were cross-linked to the membrane with
0.2% (v/v) glutaraldehyde in PBS-0.02% (v/v) Tween20 for
30 min, following transfer and prior to the blocking step.
m
7GTP affinity chromatography
200 mg of protein lysate from MCF-7 cells stably expressing
EGFP-LC3 were incubated with 30 ml (neat) 7-methylguanosine-
59-triphosphate sepharose 4B (m
7GTP) (#27-5025-01, GE
Healthcare) for 90 min at 4uC, mixing end-over-end. Beads were
then pelleted by centrifugation at low speed for 30 sec. Beads were
washed twice with extraction buffer supplemented with protease
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lysis and protein quantitation section. Material bound to the m
7GTP
sepharose was then eluted by boiling for 10 min with 50 ml5 x
sample buffer (200 mM Tris-HCl pH 6.8, 8% (w/v) sodium
dodecyl sulphate, 0.4% (w/v) bromophenol blue, 40% (v/v)
glycerol) containing 100 mM dithiothreitol. Eluted material was
analysed by SDS-PAGE/immunoblot with anti-4E-BP1, anti-
eIF4G and anti-eIF4G antibodies.
Supporting Information
Figure S1 Stimulation of punctate EGFP-LC3 accumulation
and EGFP-LC3 processing by rapamycin. (a) MCF-7 cells
expressing EGFP-LC3 were incubated with 20 nM rapamycin
for the indicated times and images were acquired using the
automated microscopy assay. (b) MCF-7 cells expressing EGFP-
LC3 were treated in complete medium with 20 nM rapamycin for
the indicated times. EGFP-LC3 processing was monitored by
probing lysates with anti-GFP antibody and mTORC1 activity by
probing lysates with antisera against phosphorylated (Thr389)
S6K and total S6K. (c) Quantitation of punctate EGFP-LC3
staining during 4 h incubation in complete medium or amino acid
and serum starvation using the screening assay.
Found at: doi:10.1371/journal.pone.0007124.s001 (0.71 MB TIF)
Figure S2 Illustration of screening assay and results. (a) Data
used for determination of Z-factor. Forty-eight wells were treated
for 4 h with DMSO (negative control) and 48 wells were treated
with chloroquine (positive control). Punctate EGFP-LC3 staining
was determined using the screening assay. (b) Results from one 96-
well plate of screening chemicals demonstrating quantitation of
punctate EGFP-LC3 staining, with four positive controls (chloro-
quine) and two active chemicals indicated by blue arrows. The
right panels show images obtained from the automated micros-
copy screen for an inactive chemical (top) and an active chemical
(bottom).
Found at: doi:10.1371/journal.pone.0007124.s002 (0.25 MB TIF)
Figure S3 Niclosamide, rottlerin, amiodarone and perhexiline
inhibit the amino acid-dependent phosphorylation of 4E-BP1 at
Thr37/46. MCF-7 cells stably expressing EGFP-LC3 were
incubated in Hank’s balanced salt solution supplemented with
10% (v/v) dialysed serum for 1 h or 4 h. Where indicated, cells
were simultaneously incubated with 10 mM perhexiline, 10 mM
niclosamide, 50 mM amiodarone, 3 mM rottlerin or 0.2% (v/v)
DMSO for the times indicated. (a) Lysates were probed for EGFP-
LC3 processing using GFP antibody. Tubulin staining was used as
a loading control. (b) Lysates were probed for 4E-BP phosphor-
ylation at Thr37/46 or total 4E-BP1 levels using the antisera
indicated.
Found at: doi:10.1371/journal.pone.0007124.s003 (0.16 MB TIF)
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